Decorative image

CimaVax vaccine

CimaVax is a new vaccine being developed for lung cancer.

What is it

CimaVax EGF is a vaccine treatment being developed in Cuba for non small cell lung cancer.

The vaccine targets a particular protein called epidermal growth factor (EGF). EGF occurs naturally in the body and signals to cells to grow and divide. It does this by attaching to a receptor protein on the cell surface. Some cancers make the body produce too much EGF so that the cells grow and divide uncontrollably.

The CimaVax vaccine is made up of two proteins, one of which is EGF. The vaccine works by stimulating the body’s immune response. It encourages the body to make antibodies that recognise and bind to EGF. This stops the EGF attaching to the receptors on cancer cells, so there's no signal telling the cancer cells to grow and divide. This slows the growth of the cancer.

Research into CimaVax

Several small trials using the vaccine have had promising results. The results of a phase 2 trial for people with advanced non small cell lung cancer (NSCLC) were published in early 2008. The trial involved 80 people with stage 3b and stage 4 NSCLC. Everyone in the trial had chemotherapy. After chemotherapy was complete, half of the people had the vaccine.

Trial results and side effects

The results showed that people who had the vaccine lived on average about 4 to 6 months longer. It also improved people’s quality of life by reducing symptoms such as coughing and breathlessness.

The trial results also showed that people younger than 60 did better than those who were over 60. There were 12 people under 60 who had a good immune response and their improvement in survival was greatest. They lived on average for just over 15 months compared to 7.4 months for people who didn’t have the vaccine. But this is a small group to draw any firm conclusions.

The side effects of the vaccine were mild. The most common effects were chills, fever and feeling sick.

The researchers tested whether people produced antibodies to EGF (an immune response) with a blood test. People who showed an immune response on the test did better than people who did not produce antibodies.

This research is promising but it's a small trial and we'll need more trial results before we know exactly how well the vaccine works for people with lung cancer. A  trial is currently in progress in the United States. 

CimaVax in the UK

CimaVax isn’t available at the moment in the UK and there aren't any trials at the moment.

It has been approved in Cuba and is used in hospitals there. We need more results from trials before CimaVax can become more widely available.

Last reviewed: 
12 May 2015
  • Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy

    Rodríguez PC. and others

    MEDICC review, 2010. Vol 12, issue 1

  • CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma

    Cheng JY and Kananathan R.

    Human Vaccines & Immunotherapeutics, 2012. Vol 8, issue 12

  • Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer

    Vinageras and others

    Journal of Clinical Oncology, 2008. Vol 26, issue 9

  • Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.

    García B. and others

    Clinical Cancer Research, 2008. Vol 14, issue 3

Information and help

Dangoor sponsorship

About Cancer generously supported by Dangoor Education since 2010.